Spinocerebellar Ataxia Type 15/16: Disease-Characteristics Report

Executive summary

Spinocerebellar ataxia type 15/16 (SCA15/16) is a rare, autosomal-dominant, predominantly adult-onset cerebellar disorder caused by heterozygous pathogenic variants in ITPR1, most characteristically multi-exon or whole-gene deletions producing IP3R1 haploinsufficiency. Its classic phenotype is a relatively “pure” cerebellar syndrome—gait and limb ataxia, dysarthria, nystagmus, and action/head tremor—with cerebellar vermis-predominant atrophy and unusually slow progression. Typical onset is 30–50 years, although the reported range is 7–66 years; many affected people remain independently ambulant or use only a cane 10–40 years after onset. SCA16 was shown to share the same ITPR1 loss-of-function basis as SCA15 and is now generally treated as the same entity, SCA15/16. (tada2014ip3receptorsin pages 5-8, prestori2019disruptedcalciumsignaling pages 8-10)

The core disease mechanism is impaired IP3-triggered calcium release from the endoplasmic reticulum in cerebellar Purkinje cells. Abnormal calcium homeostasis disrupts dendritic integration and firing, eventually producing Purkinje-cell dysfunction or loss and impaired cerebellar output. There is no approved disease-modifying therapy or SCA15/16-specific interventional trial; current care is genetic counseling, rehabilitation, assistive care, and symptom management. (ghorbani2023copynumbervariant pages 4-6, hisatsune2013ip3r1deficiencyin pages 1-2, shimobayashi2018calciumsignalingpkc pages 1-2, brown2012computationalanalysisof pages 1-3, matsugi2025effectsofphysiotherapy pages 1-2)

The following table provides a compact knowledge-base representation; the narrative below expands and qualifies it.

Table: This table provides a concise knowledge-base style summary of Spinocerebellar Ataxia Type 15/16, covering identifiers, genetics, phenotypes, mechanism, diagnostics, treatment, prognosis, epidemiology, and models. It also flags evidence gaps and separates classic adult-onset SCA15/16 from other ITPR1-associated disorders.

1. Disease information

Definition and nomenclature

SCA15/16 is a Mendelian neurodegenerative ataxia in the autosomal-dominant spinocerebellar ataxia group. Synonyms include spinocerebellar ataxia type 15, SCA15, spinocerebellar ataxia type 16, SCA16, SCA15/16, and, less specifically, ITPR1-associated ataxia. “SCA16” arose from a Japanese kindred but was subsequently shown to result from an ITPR1 deletion, establishing allelism with SCA15; some experts have therefore called SCA16 a “vacant SCA” designation. (ghorbani2023copynumbervariant pages 7-8, prestori2019disruptedcalciumsignaling pages 8-10)

Key identifiers

• MONDO: MONDO:0011694, spinocerebellar ataxia type 15/16. Open Targets associates this disease specifically with ITPR1. (OpenTargets Search: spinocerebellar ataxia type 15-ITPR1)
• Gene: ITPR1, Ensembl ENSG00000150995; approved name inositol 1,4,5-trisphosphate receptor type 1. (OpenTargets Search: spinocerebellar ataxia type 15-ITPR1)
• Exact OMIM, Orphanet, MeSH, ICD-10, and ICD-11 identifiers were not verified in the retrieved primary-source corpus and should be checked directly before production ingestion. ICD systems generally classify it under hereditary ataxia rather than assigning a subtype-specific code.

The evidence is primarily aggregated disease-level evidence from pedigrees, case series, diagnostic cohorts, reviews, and model systems. It is not principally an individual-EHR-derived phenotype definition.

2. Etiology, risk, and protective factors

Causal factor

The primary cause is a heterozygous germline pathogenic variant in ITPR1. Large deletions have involved exons 1–10, 1–40, 1–44, 1–48, most or all of the gene, and sometimes adjacent SUMF1 or SETMAR sequence. The recurring observation that heterozygous SUMF1 deficiency does not cause a movement disorder, together with reduced ITPR1 RNA/protein in deletion carriers, identifies ITPR1 haploinsufficiency—not SUMF1 loss—as the causal mechanism. (hisatsune2017ip3receptormutations pages 10-13, hisatsune2017ip3receptormutations pages 7-10, ghorbani2023copynumbervariant pages 2-4, ghorbani2023copynumbervariant pages 4-6)

Reported SCA15/16 missense substitutions include p.Pro1059Leu and p.Val494Ile. p.Pro1059Leu lies in a regulatory region and showed approximately twofold greater IP3-binding affinity than wild-type receptor in one experimental context, indicating that not every allele is a simple null and that variant effects may be cell-type dependent. (hisatsune2017ip3receptormutations pages 10-13)

Risk factors

• Genetic: carrying a pathogenic heterozygous ITPR1 allele and having an affected parent are the established risks. Each child of a heterozygous affected individual ordinarily has a 50% transmission probability.
• Age: penetrance is plausibly age-dependent because onset can be late, but a reliable age-specific penetrance curve is unavailable.
• Sex: no established sex bias.
• Environmental, infectious, occupational, diet, alcohol, smoking, or toxin risks: none are established as causes or modifiers of SCA15/16. Such exposures remain important differential causes of acquired ataxia, not demonstrated SCA15/16 risk factors. (coarelli2023theinheritedcerebellar pages 1-2)
• Protective factors or modifier genes: no validated genetic or environmental protective factor was identified.
• Gene–environment interaction: no disease-specific interaction has been established.

3. Phenotypes

The classic phenotype is a slowly progressive, predominantly pure cerebellar syndrome. Available publications are small and do not support robust percentages for most individual findings. Suggested ontology mappings should therefore carry qualitative rather than fabricated frequencies.

• Gait and balance ataxia: usually the presenting or dominant sign; chronic and slowly progressive. Suggested HPO: Ataxia, Gait ataxia, Unsteady gait.
• Limb dysmetria/ataxia and truncal ataxia: common cerebellar signs. Suggested HPO: Limb ataxia, Truncal ataxia, Dysmetria.
• Dysarthria/ataxic speech: common but variably present. Suggested HPO: Dysarthria.
• Oculomotor abnormalities: gaze-evoked nystagmus and impaired oculocephalic reflex have been described. Suggested HPO: Nystagmus, Abnormality of ocular movements.
• Tremor: postural, action/intention, and head tremor may precede or accompany gait ataxia. Suggested HPO: Intention tremor, Postural tremor, Head tremor.
• Hyperreflexia: may occur without spasticity or extensor plantar responses. Suggested HPO: Hyperreflexia.
• Episodic dystonic symptoms: described in some cases but not a defining or consistently frequent feature. Suggested HPO: Dystonia. (prestori2019disruptedcalciumsignaling pages 8-10)
• Peripheral neuropathy: atypical but possible. In the 2023 Dutch father–daughter pair, both had limb ataxia and vermian atrophy; only the father had dysarthria and polyneuropathy, illustrating variable expressivity. (ghorbani2023copynumbervariant pages 2-4, ghorbani2023copynumbervariant pages 4-6)
• Cognition and epilepsy: cognition is usually preserved, and epilepsy is not characteristic of classic SCA15/16. Developmental delay, intellectual disability, congenital ataxia, craniofacial anomalies, aniridia, or fixed congenital mydriasis should prompt consideration of other ITPR1 phenotypes rather than automatic expansion of the SCA15/16 phenotype. (tada2014ip3receptorsin pages 5-8, kleyner2023itpr1associatedspinocerebellarataxia pages 18-21)

Quality-of-life impact

Disease-specific EQ-5D, SF-36, or PROMIS datasets were not found. Expected burdens include falls, restricted community mobility, difficulty with fine motor tasks, impaired speech intelligibility, loss of driving or employment capacity, and increasing need for aids. The unusually slow course can preserve independence for decades, but chronic imbalance and tremor still produce meaningful disability.

4. Genetic and molecular information

ITPR1 encodes IP3R1, a tetrameric, IP3-gated calcium-release channel in the endoplasmic-reticulum membrane. The disorder is usually caused by germline heterozygous deletion or other loss of function. Somatic variants are not an established cause. Population frequencies for individual pathogenic alleles were not available in the retrieved evidence; causal large deletions are expected to be absent or exceptionally rare in reference populations.

A 2023 Dutch study identified a 260.8-kb heterozygous deletion at 3p26.1, GRCh37 coordinates 4,503,353–4,764,171, removing ITPR1 exons 1–41 and SUMF1 exons 1–2 in a father and daughter. The deletion was represented by 108 SNP probes and absent from 3,280 internal controls. Both patients developed symptoms at approximately age 40 and had slow progression and vermian atrophy. (ghorbani2023copynumbervariant pages 2-4, ghorbani2023copynumbervariant pages 4-6)

No validated modifier gene or SCA15/16-specific DNA-methylation, histone, or chromatin signature has been established. No recurrent aneuploidy or balanced rearrangement defines the disease; the relevant structural lesions are focal heterozygous CNV deletions at the ITPR1 locus.

5. Environmental information

SCA15/16 is not infectious, toxic, nutritional, or occupational in origin. No pathogen, radiation exposure, pollutant, lifestyle behavior, or environmental prophylaxis is known to alter its occurrence. Alcohol and sedating or cerebellotoxic drugs may pragmatically worsen balance in any ataxic patient, but this is symptom aggravation rather than demonstrated disease modification. Acquired toxic, autoimmune, vascular, metabolic, and infectious ataxias must nevertheless be excluded during diagnosis. (coarelli2023theinheritedcerebellar pages 1-2)

6. Mechanism and pathophysiology

Causal chain

1. A heterozygous deletion or functionally disruptive ITPR1 variant reduces or alters IP3R1.
2. IP3R1-mediated release of calcium from the smooth ER is reduced or mistimed.
3. Purkinje cells are disproportionately vulnerable because IP3R1 is highly expressed in their soma and dendrites and supports mGluR1–PLC–IP3 calcium signaling, synaptic plasticity, dendritic integration, and firing precision.
4. Calcium-homeostasis disturbance impairs dendritic development or maintenance, synaptic integration, and Purkinje-cell firing.
5. Purkinje dysfunction and later degeneration disturb inhibitory output from cerebellar cortex to deep cerebellar nuclei, producing gait/limb incoordination, dysarthria, oculomotor signs, and tremor. (ghorbani2023copynumbervariant pages 4-6, prestori2019disruptedcalciumsignaling pages 8-10, hisatsune2013ip3r1deficiencyin pages 1-2, shimobayashi2018calciumsignalingpkc pages 1-2)

Direct mechanistic quotation: the 2023 CNV study states that deletion of one ITPR1 copy produces reduced RNA and protein and that “haploinsufficiency of ITPR1 is very likely the underlying disease mechanism”; it further links haploinsufficiency to “aberrant intracellular Ca2+ homeostasis and dysfunction of Purkinje cells that ultimately causes their degeneration.” (ghorbani2023copynumbervariant pages 4-6)

Suggested GO concepts include inositol trisphosphate-mediated signaling, calcium ion release from endoplasmic reticulum, regulation of cytosolic calcium ion concentration, regulation of synaptic plasticity, Purkinje cell development, and neuron projection development. Relevant cellular compartments are the endoplasmic-reticulum membrane, Purkinje-cell soma, and dendritic arbor. Suggested cell type: cerebellar Purkinje cell.

There is no established SCA15/16-specific inflammatory, immune, metabolomic, lipidomic, single-cell, spatial-transcriptomic, proteomic, or epigenomic signature. Computational modeling predicts that increasing residual IP3R1 sensitivity might normalize calcium responses when receptor abundance is not too low, but this remains a preclinical hypothesis, not a treatment recommendation. (brown2012computationalanalysisof pages 1-3)

7. Anatomical structures affected

The primary organ is the central nervous system, particularly the cerebellum. MRI usually shows marked cerebellar vermis atrophy with milder hemispheric atrophy; bilateral, symmetric involvement is expected rather than focal lateralization. The principal tissue is cerebellar cortex and the key cell population is the Purkinje neuron. Functional downstream structures include deep cerebellar nuclei, inferior olive, brainstem, and cerebello-thalamo-cortical motor networks. (tada2014ip3receptorsin pages 5-8, ghorbani2023copynumbervariant pages 4-6, hisatsune2013ip3r1deficiencyin pages 1-2)

Suggested terms: UBERON cerebellum, cerebellar cortex, cerebellar vermis, cerebellar hemisphere, inferior olivary complex; CL Purkinje cell; GO cellular component endoplasmic reticulum membrane. Exact IDs should be validated against current ontology releases.

8. Temporal development

Onset is insidious and most often adult, usually 30–50 years, with a reported 7–66-year range. The course is chronic, lifelong, and very slowly progressive rather than episodic or relapsing-remitting. A practical staging scheme is: early imbalance/tremor; established gait and limb ataxia with dysarthria/ocular signs; and later mobility-aid dependence. Formal SCA15/16 stages or validated progression coefficients are unavailable. Most reported individuals remain independently ambulant or use a cane 10–40 years after onset. No spontaneous or treatment-induced remission pattern is recognized. (tada2014ip3receptorsin pages 5-8)

9. Inheritance and population

Inheritance is autosomal dominant, with variable expressivity and likely age-dependent penetrance. Genetic anticipation is not expected because SCA15/16 is not a repeat-expansion disorder. Germline mosaicism has been reported in broader ITPR1-associated developmental ataxia, but is not established as a common mechanism in classic SCA15/16. Founder effects, consanguinity, carrier frequency, and sex ratio are insufficiently characterized. (kleyner2023itpr1associatedspinocerebellarataxia pages 18-21)

Population prevalence and incidence are unknown. Family-cohort estimates cited in reviews include approximately 2.7% of Australian dominant-ataxia families, 1.8% of 333 White/Caucasian dominant-ataxia families, and 8.9% in a Central European series, with rarity in Japanese cohorts. These are diagnostic proportions, not general-population prevalence estimates. (tada2014ip3receptorsin pages 5-8)

In the 2023 Dutch cohort, 338 unsolved ataxia patients were screened; after exclusion of 46 low-quality samples, 3/292 (1%) carried potentially relevant SCA-gene deletions. Two were related individuals with the same pathogenic ITPR1 deletion, so this does not imply a 0.68% population prevalence. (ghorbani2023copynumbervariant pages 2-4, ghorbani2023copynumbervariant pages 1-2)

10. Diagnostics

Clinical and imaging assessment

Evaluate slowly progressive cerebellar gait disorder, limb dysmetria, dysarthria, ocular motor signs, and tremor; obtain a three-generation pedigree and brain MRI. MRI evidence of vermian-predominant cerebellar atrophy supports but does not establish the diagnosis. SARA or ICARS can quantify severity, but neither is a diagnostic biomarker. No validated blood, CSF, urine, electrophysiologic, biopsy, proteomic, or metabolomic biomarker is specific for SCA15/16. (tada2014ip3receptorsin pages 5-8, coarelli2023theinheritedcerebellar pages 1-2)

Genetic strategy

1. Exclude acquired and treatable ataxias and common repeat expansions appropriate to ancestry and phenotype.
2. Use a hereditary-ataxia panel, WES, or WGS that includes ITPR1 sequence and CNV calling.
3. If CNV sensitivity is uncertain, perform MLPA, quantitative dosage analysis, chromosomal microarray/SNP array, or validated read-depth analysis.
4. Confirm the variant and perform segregation/cascade testing when relatives are available.

A major 2023 practical conclusion was: “we suggest adding CNV analysis alongside SNV analysis to SCA gene diagnostics using next-generation sequencing approaches, at least for ITPR1.” (ghorbani2023copynumbervariant pages 1-2)

Conventional karyotyping is usually too insensitive. FISH is not first line but can confirm a known locus deletion. Mitochondrial testing and repeat-expansion assays are useful for differential diagnosis, not for detecting the canonical SCA15/16 lesion. WES can detect coding SNVs but may miss or incompletely resolve CNVs; WGS offers more uniform CNV and breakpoint detection.

Differential diagnosis

Important alternatives include SCA5, SCA6, SCA11, SCA14, SCA26, FGF14-related ataxia/SCA27B, other dominant SCAs, CANVAS, FXTAS, immune-mediated ataxia, alcohol/drug toxicity, and structural cerebellar disease. ITPR1 allelic disorders require particular care:

• SCA15/16: usually adult-onset, slowly progressive, relatively pure cerebellar ataxia, often deletion/haploinsufficiency.
• SCA29: congenital or infantile-onset, usually nonprogressive developmental ataxia with motor delay and sometimes cognitive involvement, often missense variants.
• Gillespie syndrome: congenital aniridia/iris hypoplasia plus cerebellar ataxia and developmental impairment.

The 2023 p.Thr267Met family—with developmental delay, intellectual disability, craniofacial findings, and presumed germline mosaicism—fits a broader SCA29-like ITPR1 disorder and should not be used to redefine classic SCA15/16. (prestori2019disruptedcalciumsignaling pages 8-10, kleyner2023itpr1associatedspinocerebellarataxia pages 18-21)

11. Outcome and prognosis

No 5- or 10-year survival estimates, mortality rate, or disease-specific life-expectancy analysis is available. Classic SCA15/16 is not generally associated with early death; severe bulbar complications and epilepsy are not typical. Morbidity is mainly progressive mobility, coordination, speech, and fall-related disability. Recovery of lost neurologic function is not expected, although compensatory function can improve with rehabilitation and aids. Earlier onset, broader neurologic involvement, and more severe baseline ataxia may plausibly predict greater lifetime disability, but no validated SCA15/16 prognostic model or molecular biomarker exists. (tada2014ip3receptorsin pages 5-8)

12. Treatment and current implementation

No approved pharmacologic, gene, cell, RNA, immunologic, or surgical therapy modifies SCA15/16 progression. No SCA15/16-specific interventional NCT study was identified; a broad rare-disease registry, NCT01793168, is observational rather than a treatment trial.

Real-world care is multidisciplinary:

• physical therapy emphasizing balance, coordination, gait, strength, and aerobic conditioning;
• occupational therapy, home-safety modification, and adaptive equipment;
• cane, walker, or wheelchair assessment as required;
• speech-language therapy and swallowing assessment if symptoms arise;
• individualized treatment of tremor, dystonia, sleep, mood, pain, or neuropathy;
• fall prevention and avoidance of unnecessarily sedating/cerebellotoxic medication.

Suggested MAXO concepts include physical therapy, gait training, balance training, occupational therapy, speech therapy, assistive-device use, brain MRI, molecular genetic testing, and genetic counseling.

The latest retrieved rehabilitation synthesis was published 10 January 2025, based on a search completed in 2024. Across 18 randomized trials and 398 people with degenerative cerebellar ataxia, 315 contributed to SARA meta-analysis; physiotherapy improved SARA by a mean −1.41 points (95% CI −2.16 to −0.66). Multi-aspect training, balance training, and aerobic training had respective mean differences of −1.59, −1.58, and −1.65 points, but certainty was low and risk of bias serious. These data support rehabilitation generally, not a proven SCA15/16-specific effect. DOI: 10.3389/fneur.2024.1491142. (matsugi2025effectsofphysiotherapy pages 1-2)

13. Prevention

There is no vaccine, lifestyle prophylaxis, or population/newborn screening program. Primary prevention is reproductive: genetic counseling, cascade testing, and—where desired and legally available—prenatal diagnosis or preimplantation genetic testing after identification of a familial pathogenic variant. Secondary prevention consists of presymptomatic testing in competent at-risk adults after counseling and early surveillance for balance impairment. Tertiary prevention includes rehabilitation, fall prevention, assistive devices, and management of secondary deconditioning. Predictive testing in minors is generally deferred for an adult-onset disorder unless a clear childhood medical benefit exists.

14. Other species and natural disease

Mus musculus (NCBI Taxonomy 10090) has an orthologous Itpr1 gene and several spontaneous or engineered movement-disorder alleles. These are experimental or laboratory-observed models; a naturally occurring veterinary homolog in a defined companion-animal breed was not established in the retrieved evidence. SCA15/16 is not transmissible and has no zoonotic potential.

15. Model organisms

Mouse models include heterozygous and null Itpr1 mice, Itpr1 Δ18/wild-type and Δ18/Δ18 alleles, and conditional Wnt1-Cre;Itpr1 flox/flox deletion in cerebellum/brainstem. Heterozygous mice show motor discoordination; homozygous or tissue-specific severe depletion produces marked ataxia/dystonia, abnormal Purkinje-cell complex-spike patterns, feeding difficulty, and shortened survival. Inactivation of the cerebellum or inferior olive—and experimental removal of Purkinje cells—ameliorated dystonic output in the conditional model, demonstrating an olivocerebellar circuit origin independent of basal ganglia. (hisatsune2013ip3r1deficiencyin pages 1-2, brown2012computationalanalysisof pages 1-3)

These models strongly support dosage-sensitive IP3R1/Purkinje-cell physiology but can be more severe than heterozygous human SCA15/16 and therefore incompletely model its late onset and very slow progression. Computational Purkinje-cell models provide a complementary platform for testing how receptor abundance and sensitivity shape calcium release and membrane electrophysiology. (brown2012computationalanalysisof pages 1-3)

Recent developments and evidence gaps

The most directly relevant recent advance is the February 2023 Dutch CNV study, DOI 10.1212/NXG.0000000000200050. It showed that large SCA-gene CNVs were rare but clinically decisive and argued that ITPR1 CNV analysis should be integrated with SNV analysis in modern NGS workflows. Its abstract reports: “Of the 338 patients with cerebellar ataxia, we identified putative clinically relevant CNV deletions in 3 patients,” including the pathogenic ITPR1 deletion in two related patients. (ghorbani2023copynumbervariant pages 1-2)

The October 2023 p.Thr267Met report, DOI 10.1101/mcs.a006303, added evidence for parental germline mosaicism and craniofacial involvement across the wider ITPR1 disease spectrum, but its developmental SCA29-like phenotype is not classic SCA15/16. (kleyner2023itpr1associatedspinocerebellarataxia pages 18-21)

No disease-specific 2024 natural-history cohort, biomarker validation, omics atlas, or therapeutic trial was identified. Major knowledge gaps remain population prevalence, age-specific penetrance, longitudinal SARA progression, patient-reported quality of life, genotype–phenotype prediction for missense alleles, and disease-specific treatment response. Therefore, exact phenotype percentages, survival estimates, environmental modifiers, protective alleles, and treatment response rates should be recorded as unknown, rather than inferred from other SCA subtypes.

References

1. (tada2014ip3receptorsin pages 5-8): Masayoshi Tada, Masatoyo Nishizawa, and Osamu Onodera. Ip3 receptors in neurodegenerative disorders: spinocerebellar ataxias and huntington’s and alzheimer’s diseases. ArXiv, pages 579-600, Nov 2014. URL: https://doi.org/10.1007/978-3-642-40282-1_28, doi:10.1007/978-3-642-40282-1_28. This article has 2 citations.

2. (prestori2019disruptedcalciumsignaling pages 8-10): Francesca Prestori, Francesco Moccia, and Egidio D’Angelo. Disrupted calcium signaling in animal models of human spinocerebellar ataxia (sca). International Journal of Molecular Sciences, 21:216, Dec 2019. URL: https://doi.org/10.3390/ijms21010216, doi:10.3390/ijms21010216. This article has 42 citations.

3. (ghorbani2023copynumbervariant pages 4-6): Fatemeh Ghorbani, Eddy N. de Boer, Marloes Benjamins-Stok, Corien C. Verschuuren-Bemelmans, Jurjen Knapper, Jelkje de Boer-Bergsma, Jeroen J. de Vries, Birgit Sikkema-Raddatz, Dineke S. Verbeek, Helga Westers, and Cleo C. van Diemen. Copy number variant analysis of spinocerebellar ataxia genes in a cohort of dutch patients with cerebellar ataxia. Neurology: Genetics, Feb 2023. URL: https://doi.org/10.1212/nxg.0000000000200050, doi:10.1212/nxg.0000000000200050. This article has 10 citations.

4. (hisatsune2013ip3r1deficiencyin pages 1-2): Chihiro Hisatsune, Hiroyuki Miyamoto, Moritoshi Hirono, Naohide Yamaguchi, Takeyuki Sugawara, Naoko Ogawa, Etsuko Ebisui, Toshio Ohshima, Masahisa Yamada, Takao K. Hensch, Mitsuharu Hattori, and Katsuhiko Mikoshiba. Ip3r1 deficiency in the cerebellum/brainstem causes basal ganglia-independent dystonia by triggering tonic purkinje cell firings in mice. Frontiers in Neural Circuits, Oct 2013. URL: https://doi.org/10.3389/fncir.2013.00156, doi:10.3389/fncir.2013.00156. This article has 68 citations.

5. (shimobayashi2018calciumsignalingpkc pages 1-2): Etsuko Shimobayashi and Josef P. Kapfhammer. Calcium signaling, pkc gamma, ip3r1 and car8 link spinocerebellar ataxias and purkinje cell dendritic development. Jan 2018. URL: https://doi.org/10.2174/1570159x15666170529104000, doi:10.2174/1570159x15666170529104000. This article has 58 citations and is from a peer-reviewed journal.

6. (brown2012computationalanalysisof pages 1-3): Sherry-Ann Brown and Leslie M Loew. Computational analysis of calcium signaling and membrane electrophysiology in cerebellar purkinje neurons associated with ataxia. BMC Systems Biology, 6:70-70, Jun 2012. URL: https://doi.org/10.1186/1752-0509-6-70, doi:10.1186/1752-0509-6-70. This article has 32 citations and is from a peer-reviewed journal.

7. (matsugi2025effectsofphysiotherapy pages 1-2): Akiyoshi Matsugi, Kyota Bando, Yuki Kondo, Yutaka Kikuchi, Kazuhiro Miyata, Yuichi Hiramatsu, Yuya Yamanaka, Hiroaki Tanaka, Yuta Okuda, Koshiro Haruyama, and Yuichiro Yamasaki. Effects of physiotherapy on degenerative cerebellar ataxia: a systematic review and meta-analysis. Frontiers in Neurology, Jan 2025. URL: https://doi.org/10.3389/fneur.2024.1491142, doi:10.3389/fneur.2024.1491142. This article has 25 citations and is from a peer-reviewed journal.

8. (OpenTargets Search: spinocerebellar ataxia type 15-ITPR1): Open Targets Query (spinocerebellar ataxia type 15-ITPR1, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

9. (hisatsune2017ip3receptormutations pages 10-13): Chihiro Hisatsune and Katsuhiko Mikoshiba. Ip3 receptor mutations and brain diseases in human and rodents. Journal of Neurochemistry, 141:790-807, Jun 2017. URL: https://doi.org/10.1111/jnc.13991, doi:10.1111/jnc.13991. This article has 86 citations and is from a domain leading peer-reviewed journal.

10. (hisatsune2017ip3receptormutations pages 7-10): Chihiro Hisatsune and Katsuhiko Mikoshiba. Ip3 receptor mutations and brain diseases in human and rodents. Journal of Neurochemistry, 141:790-807, Jun 2017. URL: https://doi.org/10.1111/jnc.13991, doi:10.1111/jnc.13991. This article has 86 citations and is from a domain leading peer-reviewed journal.

11. (ghorbani2023copynumbervariant pages 2-4): Fatemeh Ghorbani, Eddy N. de Boer, Marloes Benjamins-Stok, Corien C. Verschuuren-Bemelmans, Jurjen Knapper, Jelkje de Boer-Bergsma, Jeroen J. de Vries, Birgit Sikkema-Raddatz, Dineke S. Verbeek, Helga Westers, and Cleo C. van Diemen. Copy number variant analysis of spinocerebellar ataxia genes in a cohort of dutch patients with cerebellar ataxia. Neurology: Genetics, Feb 2023. URL: https://doi.org/10.1212/nxg.0000000000200050, doi:10.1212/nxg.0000000000200050. This article has 10 citations.

12. (ghorbani2023copynumbervariant pages 1-2): Fatemeh Ghorbani, Eddy N. de Boer, Marloes Benjamins-Stok, Corien C. Verschuuren-Bemelmans, Jurjen Knapper, Jelkje de Boer-Bergsma, Jeroen J. de Vries, Birgit Sikkema-Raddatz, Dineke S. Verbeek, Helga Westers, and Cleo C. van Diemen. Copy number variant analysis of spinocerebellar ataxia genes in a cohort of dutch patients with cerebellar ataxia. Neurology: Genetics, Feb 2023. URL: https://doi.org/10.1212/nxg.0000000000200050, doi:10.1212/nxg.0000000000200050. This article has 10 citations.

13. (kleyner2023itpr1associatedspinocerebellarataxia pages 18-21): Robert Kleyner, Nathaniel Ung, Mohammad Arif, Elaine Marchi, Karen Amble, Maureen Gavin, Ricardo Madrid, and Gholson Lyon. Itpr1-associated spinocerebellar ataxia with craniofacial features—additional evidence for germline mosaicism. Cold Spring Harbor Molecular Case Studies, 9:a006303, Oct 2023. URL: https://doi.org/10.1101/mcs.a006303, doi:10.1101/mcs.a006303. This article has 3 citations and is from a peer-reviewed journal.

14. (coarelli2023theinheritedcerebellar pages 1-2): Giulia Coarelli, Thomas Wirth, Christine Tranchant, Michel Koenig, Alexandra Durr, and Mathieu Anheim. The inherited cerebellar ataxias: an update. Journal of Neurology, 270:208-222, Sep 2023. URL: https://doi.org/10.1007/s00415-022-11383-6, doi:10.1007/s00415-022-11383-6. This article has 91 citations and is from a domain leading peer-reviewed journal.

15. (ghorbani2023copynumbervariant pages 7-8): Fatemeh Ghorbani, Eddy N. de Boer, Marloes Benjamins-Stok, Corien C. Verschuuren-Bemelmans, Jurjen Knapper, Jelkje de Boer-Bergsma, Jeroen J. de Vries, Birgit Sikkema-Raddatz, Dineke S. Verbeek, Helga Westers, and Cleo C. van Diemen. Copy number variant analysis of spinocerebellar ataxia genes in a cohort of dutch patients with cerebellar ataxia. Neurology: Genetics, Feb 2023. URL: https://doi.org/10.1212/nxg.0000000000200050, doi:10.1212/nxg.0000000000200050. This article has 10 citations.

Artifacts

• Edison artifact artifact-00